Literature DB >> 19449002

Should FDG PET/CT be used for the initial staging of breast cancer?

David Groheux1, Elif Hindié, Domenico Rubello, Marc Espié, Georges Baillet, Sylvie Giacchetti, Jean-Louis Misset, Jean-Luc Moretti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19449002     DOI： 10.1007/s00259-009-1159-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  20 in total

1.  Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer.

Authors:  Takako Nakai; Chio Okuyama; Takao Kubota; Kei Yamada; Yo Ushijima; Keiko Taniike; Takako Suzuki; Tsunehiko Nishimura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08-20       Impact factor: 9.236

2.  A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases.

Authors:  U Veronesi; C De Cicco; V E Galimberti; J R Fernandez; N Rotmensz; G Viale; G Spano; A Luini; M Intra; P Veronesi; A Berrettini; G Paganelli
Journal:  Ann Oncol       Date:  2006-12-12       Impact factor: 32.976

3.  The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer.

Authors:  David N Danforth; Luigi Aloj; Jorge A Carrasquillo; Stephen L Bacharach; Cathy Chow; JoAnne Zujewski; Millie Whatley; Barbara Galen; Maria Merino; Ronald D Neumann
Journal:  Breast Cancer Res Treat       Date:  2002-09       Impact factor: 4.872

4.  Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer.

Authors:  S Mahner; S Schirrmacher; W Brenner; L Jenicke; C R Habermann; N Avril; J Dose-Schwarz
Journal:  Ann Oncol       Date:  2008-03-19       Impact factor: 32.976

5.  Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC).

Authors:  Jennifer R Bellon; Robert B Livingston; William B Eubank; Julie R Gralow; Georgiana K Ellis; Lisa K Dunnwald; David A Mankoff
Journal:  Am J Clin Oncol       Date:  2004-08       Impact factor: 2.339

6.  Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer.

Authors:  David Groheux; Jean-Luc Moretti; Georges Baillet; Marc Espie; Sylvie Giacchetti; Elif Hindie; Christophe Hennequin; Jacques-Robert Vilcoq; Caroline Cuvier; Marie-Elisabeth Toubert; Jean-Emmanuel Filmont; Farid Sarandi; Jean-Louis Misset
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-23       Impact factor: 7.038

7.  [Sentinel node biopsy in breast cancer].

Authors:  E Hindié; D Groheux; M Espie; E Bourstyn; M-E Toubert; F Sarandi; A de Roquancourt; S Giacchetti; C Cuvier; L Cahen-Doidy; P Teyton; J-L Misset; C Maylin; J-L Moretti
Journal:  Bull Cancer       Date:  2009-06       Impact factor: 1.276

8.  Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients.

Authors:  Till A Heusner; Sherko Kuemmel; Steffen Hahn; Angela Koeninger; Friedrich Otterbach; Monia E Hamami; Klaus R Kimmig; Michael Forsting; Andreas Bockisch; Gerald Antoch; Alexander Stahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-05       Impact factor: 9.236

9.  Prognostic significance of axillary node and infraclavicular lymph node status after mastectomy.

Authors:  B Kuru; M Camlibel; S Dinc; M A Gulcelik; H Alagol
Journal:  Eur J Surg Oncol       Date:  2003-12       Impact factor: 4.424

10.  Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data.

Authors:  Selin Carkaci; Homer A Macapinlac; Massimo Cristofanilli; Osama Mawlawi; Eric Rohren; Ana M Gonzalez Angulo; Shaheenah Dawood; Erika Resetkova; Huong T Le-Petross; Wei-Tse Yang
Journal:  J Nucl Med       Date:  2009-01-21       Impact factor: 10.057
View more
  10 in total

1.  ¹⁸F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.

Authors:  Alexandre Cochet; Inna Dygai-Cochet; Jean-Marc Riedinger; Olivier Humbert; Alina Berriolo-Riedinger; Michel Toubeau; Séverine Guiu; Charles Coutant; Bruno Coudert; Pierre Fumoleau; François Brunotte
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-07       Impact factor: 9.236

2.  Staging the axilla in breast cancer patients with ¹⁸F-FDG PET: how small are the metastases that we can detect with new generation clinical PET systems?

Authors:  Dimitri Bellevre; Cécile Blanc Fournier; Odile Switsers; Audrey Emmanuelle Dugué; Christelle Levy; Djelila Allouache; Cédric Desmonts; Hubert Crouet; Jean-Marc Guilloit; Jean-Michel Grellard; Nicolas Aide
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-22       Impact factor: 9.236

3.  Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients.

Authors:  C Riegger; J Herrmann; J Nagarajah; J Hecktor; S Kuemmel; F Otterbach; S Hahn; A Bockisch; T Lauenstein; G Antoch; T A Heusner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-06       Impact factor: 9.236

Review 4.  Role of Positron Emission Tomography-Computed Tomography in Locally Advanced Breast Cancer.

Authors:  Pankaj Kumar Garg; Suryanarayana V S Deo; Rakesh Kumar
Journal:  Indian J Surg Oncol       Date:  2015-07-02

5.  Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years.

Authors:  Christopher C Riedl; Elina Slobod; Maxine Jochelson; Monica Morrow; Debra A Goldman; Mithat Gonen; Wolfgang A Weber; Gary A Ulaner
Journal:  J Nucl Med       Date:  2014-09-11       Impact factor: 10.057

6.  Defining the role of PET-CT in staging early breast cancer.

Authors:  Ashley M Groves; Manu Shastry; Simona Ben-Haim; Irfan Kayani; Anmol Malhotra; Timothy Davidson; Tina Kelleher; Diane Whittaker; Marie Meagher; Brian Holloway; Ruth M Warren; Peter J Ell; Mohammed R Keshtgar
Journal:  Oncologist       Date:  2012-04-26

Review 7.  Opportunities for PET to deliver clinical benefit in cancer: breast cancer as a paradigm.

Authors:  Ian N Fleming; Fiona J Gilbert; Ken A Miles; David Cameron
Journal:  Cancer Imaging       Date:  2010-07-06       Impact factor: 3.909

8.  Synchronous Malignancies Identified by PET-CT Scan in Breast Cancer Patients.

Authors:  Maya Paran; Katerina Shulman; Boris Kessel; Jasmin Dagan
Journal:  Rambam Maimonides Med J       Date:  2022-04-26

9.  Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.

Authors:  David Groheux; Elif Hindié; Marc Delord; Sylvie Giacchetti; Anne-sophie Hamy; Cédric de Bazelaire; Anne de Roquancourt; Laetitia Vercellino; Marie-Elisabeth Toubert; Pascal Merlet; Marc Espié
Journal:  J Natl Cancer Inst       Date:  2012-12-12       Impact factor: 13.506

10.  Clinical impact of (18)F-FDG PET/CT on initial staging and therapy planning for breast cancer.

Authors:  Bengul Gunalp; Semra Ince; Alper Ozgur Karacalioglu; Asli Ayan; Ozdes Emer; Engin Alagoz
Journal:  Exp Ther Med       Date:  2012-08-09       Impact factor: 2.447
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.